Ribosomal S6 kinase (S6K), a downstream effector of the PI3K/Akt pathway, is frequently activated in human ovarian cancer [5] and is significantly more prevalent in malignant tumors than in benign lesions. This evidence concerns the gene RPS6KB1 and cancer.